Navigation Links
FDA Approved Nerve-Stimulation Therapy Now Available In New York

Vagus Nerve Stimulation therapy is a FDA approved long-term treatment regime for patients with treatment resistant depression (TRD). // This form of therapy is now being offered to patients at NewYork-Presbyterian Hospital/Columbia University Medical Center.

The treatment is now the first treatment specifically approved for TRD in patients over 18 years of age in whom antidepressant therapy has been unsuccessful atleast in four or more of the depressive episodes.

The treatment is instituted with the help of a small pacemaker-like device implanted in the chest area. The device sends mild pulses to the brain through the vagus nerve in the neck. A generator that runs under the skin to the left vagus nerve powers the device through a thin insulated wire.

The vagus nerve is one of the 12 cranial nerves and serves as the body’s information highway connecting the brain to many major organs. Several studies have shown that VNS Therapy may modulate neurotransmitters such as serotonin and norepinephrine thought to be involved in mood regulation.

Major depressive disorder is one of the most prevalent and serious illnesses in the U.S., affecting nearly 19 million Americans every year and more than 4 million people do not respond to conventional treatment such as psychotherapy, antidepressant medications, and even electroconvulsive therapy.

Nearly half of patients with an average of 25 years of major depressive disorder and multiple treatment trials realized some clinical benefit; one-third of patients had at least a 50 percent improvement in their depression; and one out of six was depression-free after treatment with VNS Therapy. Patients also reported significant improvements in quality-of-life areas, such as vitality, mental health, emotional well-being, and social functioning.

The new form of treatment is an important development in people with depression who need safe and effective therapeutic options. Several studie s have revealed the sustained beneficial efforts of the therapy over a considerable length of time. In addition, is it associated with better patient compliance and fewer side effects
'"/>




Related medicine news :

1. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
2. New FDA Approved Drug To Treat Migraine
3. New FDA Approved Drug NATRECOR For Heart Failure Patients
4. New Oral Rinse For Gingivitis Approved By FDA
5. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
6. AIDS Generic Drugs Approved by FDA for Sale in US
7. Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
8. Pfizer’s Eraxis Approved By The FD
9. Inhalers for Kids Was Approved By the FDA
10. Alcoholism Drug Vivitrol Approved By FDA
11. Drug Approved to Curb Alcohol Dependency
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/18/2017)... CA (PRWEB) , ... February 18, 2017 , ... ... paragraph presets. Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 ... and so many other applications. Users can pick and choose from hand-crafted ...
(Date:2/17/2017)... Davidson, NC (PRWEB) , ... February 17, 2017 , ... ... Davidson Commons Shopping Center in Davidson, NC. Dr. Brian Seese leads the practice as ... of dental services under one roof. Smiles by Seese serves patients of all ages ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare ... designed to further positively impact the health and wellness of our community in ... it our duty to seriously consider releasing our assets beyond our 5% targeted ...
(Date:2/17/2017)... Nashville, TN (PRWEB) , ... February 17, 2017 ... ... Services, Inc. (ISTS) brings its educational assistance management solution to the exhibit floor ... Convention Center in Orlando, Fla. , From Feb. 19–23, 2017, more than ...
(Date:2/17/2017)... Verdes, CA (PRWEB) , ... February 17, 2017 ... ... emotional flow is Dr. Carol Francis' goals for each and every ... Conference, Dr. Carol Francis will demonstrate five different brainwave tools which help energize ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... Ontario , Feb. 16, 2017  Aralez Pharmaceuticals ... global specialty pharmaceutical company, today announced that executive management ... Conference to be held February 22-23, 2017. Adrian ... of the Company at 1:35 p.m. local time on ... and audio archive for the event may be accessed ...
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that Vincent J. Angotti ... a member of the company,s board of directors, ... over two decades of experience leading executive and ...
Breaking Medicine Technology: